<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>How It Works | LiquidMammo™</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="description"
        content="How LiquidMammo™ works: a microRNA-based blood test that complements breast cancer screening, especially in dense breast tissue." />

  <!-- Stylesheet -->
  <link rel="stylesheet" href="assets/css/styles.css" />
  <link rel="icon" href="favicon.png" type="image/png" />
</head>

<body>

<!-- ======================================
     MINIMAL HEADER
======================================= -->
<header class="container">
  <nav>
    <a href="index.html">← Home</a>
  </nav>
</header>


<!-- ======================================
     MAIN CONTENT
======================================= -->
<main class="container">

  <h1>How LiquidMammo™ Works</h1>

  <!-- Overview -->
  <section class="section-tight">
    <p>
      LiquidMammo™ is a supplemental, non‑invasive blood‑based test that analyzes
      <strong>cancer‑associated microRNA signatures</strong> to support breast‑cancer screening —
      especially in <strong>dense‑breast populations</strong>.
    </p>

    <p class="notice" style="margin-top:14px;">
      LiquidMammo is being developed as a
      <strong>CLIA Laboratory Developed Test (LDT)</strong>.
      It is not yet FDA‑cleared or FDA‑approved.
    </p>
  </section>


  <!-- Step-by-step -->
  <section class="panel-light section-tight">
    <h2>The process</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr)); margin-top:20px;">

      <div class="card-mini">
        <h4>1 — Ordered by clinician</h4>
        <p class="small">
          The test is ordered through a clinician, like routine laboratory assays.
          A standard blood draw is all that is required.
        </p>
      </div>

      <div class="card-mini">
        <h4>2 — Plasma processing</h4>
        <p class="small">
          Blood is collected, stabilized, and processed under validated SOPs to preserve circulating
          <span class="scientific-term">microRNAs</span>.
        </p>
      </div>

      <div class="card-mini">
        <h4>3 — microRNA panel analysis</h4>
        <p class="small">
          A proprietary multi‑marker panel quantifies dysregulation patterns associated with tumor biology.
        </p>
      </div>

      <div class="card-mini">
        <h4>4 — Classification & interpretation</h4>
        <p class="small">
          Machine‑learning models integrate the signal with reference distributions and density‑aware context.
        </p>
      </div>

      <div class="card-mini">
        <h4>5 — Clinician‑ready report</h4>
        <p class="small">
          The final report includes result category, contextual notes, and follow‑up recommendations.
        </p>
      </div>

    </div>
  </section>


  <!-- Science -->
  <section class="section-tight">
    <h2>Why microRNAs?</h2>

    <p>
      <span class="scientific-term">microRNAs</span> regulate gene expression and are central to
      proliferation, immune signaling, and oncogenic stress responses.
      They remain stable in blood and can show dysregulation early in tumor development — often before
      structural changes appear on imaging.
    </p>
  </section>


  <!-- Dense breast rationale -->
  <section class="panel-light section-tight">
    <h2>Addressing dense‑breast limitations</h2>

    <ul class="list-tight">
      <li>Mammography sensitivity may fall to ~61% in extremely dense tissue.</li>
      <li>Dense tissue can mask small or early‑stage lesions.</li>
      <li>Interval cancers occur more frequently in dense‑breast populations.</li>
      <li>A biological signal provides density‑independent consistency.</li>
    </ul>
  </section>


  <!-- Clinical pathways -->
  <section class="section-tight">
    <h2>The role of LiquidMammo in screening pathways</h2>

    <p class="small">
      LiquidMammo is a supplemental tool intended to strengthen screening workflows by adding a
      molecular layer that complements imaging.
    </p>

    <ul class="list-tight" style="margin-top:10px;">
      <li>Clarifying equivocal imaging results</li>
      <li>Supporting decisions in dense‑breast patients</li>
      <li>Providing information for patients who defer mammography</li>
      <li>Enhancing confidence between screening intervals</li>
    </ul>
  </section>

</main>


<!-- ======================================
     FOOTER
======================================= -->
<footer>
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br />
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC and operates out of
        LabCentral in Cambridge, MA.
      </p>
    </div>

    <div class="footer-logo" style="justify-content:flex-end; text-align:right;">
      <img src="assets/logos/multiomics-logo.png" alt="MultiOmics logo" />
      <div class="footer-note" style="line-height:1.2">
        Developed by<br />MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    <a href="privacy.html">Privacy & Compliance</a> •
    <a href="contact.html">Contact
